Helen Sheldon

3.6k citations

32 papers · 2.4k indexed · 1 hit paper · h-index 19

Impact in

Cancer Research top 1%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
Molecular Biology top 5%
- Circular RNAs in diseases
- Extracellular vesicles in disease
- RNA modifications and cancer
- Angiogenesis and VEGF in Cancer
- RNA Research and Splicing

Papers in

Cancer Research 13
- Cancer, Hypoxia, and Metabolism 7
- MicroRNA in disease regulation 5
- Cancer-related molecular mechanisms research 4
Immunology and Allergy 4
- Cell Adhesion Molecules Research 4

Co-authors: Adrian L. Harris Francesca M. Buffa Jiannis Ragoussis Christos Sotiriou Jonathan Gleadle Stefano Colella John Moore Carme Camps
Journals: Oncotarget (3 papers)Cancer Research (3 papers)Clinical Cancer Research (2 papers)Angiogenesis (2 papers)Oncogene (2 papers)
Partner nations: United Kingdom United States Greece

In The Last Decade

Helen Sheldon

32 papers receiving 2.4k citations

Hit Papers

align trajectories log scale

hsa-miR-210 Is Induced by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer 2008 · 540 citations

Peers

Countries citing papers authored by Helen Sheldon

Since Specialization

Citations

This map shows the geographic impact of Helen Sheldon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Sheldon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Sheldon more than expected).

Fields of papers citing papers by Helen Sheldon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Sheldon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Sheldon. The network helps show where Helen Sheldon may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Helen Sheldon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Helen Sheldon Line = papers co-authored together Helen Sheldon links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer Journal of Experimental & Clinical Cancer Research ·Ellen C. de Heer, Christos E. Zois, Edward G. Bridges, Bert van der Vegt, Helen Sheldon, Yvonne Ng, Mieke C. Zwager, Tineke van der Sluis, Syed Haider, Tatsuo Morita, Otto Baba, C.P. Schröder, Steven de Jong, Adrian L. Harris, Mathilde Jalving	2023	9
2	Single cell RNA‐sequencing: A powerful yet still challenging technology to study cellular heterogeneity BioEssays ·Feng Jian-jun, 基安村, Helen Sheldon, Anjali Arora, Francesca M. Buffa	2022	33
3	ELTD1 is present in extracellular vesicles derived from endothelial cells as a cleaved extracellular domain which induces in vivo angiogenesis SHILAP Revista de lepidopterología ·Helen Sheldon, Wei Zhang, Esther Bridges, Gusmão Alex, RongChang Zeng, Massimo Masiero, Demin Li, Penny A. Handford, Pat Whiteman, Román Fischer, Francesca M. Buffa, Manu Vatish, Alison H. Banham, Adrian L. Harris	2022	4
4	ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression Molecular Cancer Research ·Helen Sheldon, Esther Bridges, Ildefonso Silva, Massimo Masiero, Judith Vilsmeier, Dian Wang, Russell Leek, Cameron Snell, Ioannis Roxanis, Shweta Kumar, Uzi Gileadi, Francesca M. Buffa, Alison H. Banham, Adrian L. Harris	2021	7
5	Elevated expression of the adhesion GPCR ADGRL4/ELTD1 promotes endothelial sprouting angiogenesis without activating canonical GPCR signalling Scientific Reports ·Judith Vilsmeier, Ines Liebscher, Ali Jazayeri, Aminullah Nuuri, Helen Sheldon, Alison H. Banham, Adrian L. Harris	2021	16
6	RHOQ is induced by DLL4 and regulates angiogenesis by determining the intracellular route of the Notch intracellular domain Angiogenesis ·Esther Bridges, Helen Sheldon, Giuseppe Muccari, Evelyn Ramberger, Christos E. Zois, Alun R. Barnard, Ulrike Harjes, Ji‐Liang Li, Massimo Masiero, Robert E. MacLaren, Adrian L. Harris	2020	18
7	Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer Proceedings of the National Academy of Sciences ·Matteo Morotti, Esther Bridges, Alessandro Valli, Hani Choudhry, Helen Sheldon, Simon Wigfield, Nicki Gray, Christos E. Zois, Fiona Grimm, Dylan T. Jones, Eugene Teoh, Wei‐Chen Cheng, Simon Lord, Dimitrios Anastasiou, Syed Haider, Alan McIntyre, Deborah C. I. Goberdhan, Francesca M. Buffa, Adrian L. Harris	2019	105
8	Abstract 777: ELTD1/ADGRL4, a novel adhesion GPCR regulator of tumour angiogenesis, suppresses lipid metabolism in endothelial cells, and is upregulated in breast cancer endothelium and epithelium Cancer Research ·Judith Vilsmeier, Aminullah Nuuri, Helen Sheldon, Massimo Masiero, Demin Li, Ali Jazayeri, Alison H. Banham, Adrian L. Harris	2017	2
9	Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4 Oncogene ·Ulrike Harjes, Esther Bridges, Kshipra M. Gharpure, Ioannis Roxanis, Helen Sheldon, Fabrizio Miranda, Bassel Kanaan, Sunila Pradeep, Gabriel Lopez‐Berestein, Ayaz Ahmed, Barbara A. Fielding, Anil K. Sood, Adrian L. Harris	2016	58
10	Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer Oncotarget ·赵磊, Ioannis Roxanis, Helen Sheldon, Francesca M. Buffa, Jiliang Li, Adrian L. Harris, Anthony Kong	2015	31
11	Metronomic vinorelbine: Anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition International Journal of Oncology ·Peter Bobbin, Helen Sheldon, Evangelos Briasoulis, Μάριος Μαρσέλος, Periklis Pappas, Adrian L. Harris	2015	29
12	microRNA-Associated Progression Pathways and Potential Therapeutic Targets Identified by Integrated mRNA and microRNA Expression Profiling in Breast Cancer Cancer Research ·Francesca M. Buffa, Carlos Camps, Laura Winchester, Cameron Snell, Harriet E. Gee, Helen Sheldon, Marian Taylor, Adrian L. Harris, Jiannis Ragoussis	2011	251
13	DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo Cancer Research ·Jiliang Li, Richard C.A. Sainson, Chern Ein Oon, Helen Turley, Russell Leek, Helen Sheldon, Esther Bridges, Wen Shi, Cameron Snell, Emma T. Bowden, Herren Wu, Partha S. Chowdhury, Angela J. Russell, Craig P. Montgomery, Richard Poulsom, Adrian L. Harris	2011	187
14	The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis British Journal of Cancer ·Harriet E. Gee, Francesca M. Buffa, Carlos Camps, Anassuya Ramachandran, Russell Leek, M Taylor, Meena Patil, Helen Sheldon, Guy Betts, Jarrod J. Homer, Catharine West, Jiannis Ragoussis, Adrian L. Harris	2011	238
15	Identification and angiogenic role of the novel tumor endothelial marker CLEC14A Oncogene ·Mauro Dalla Mura, R Swain, Xiaodong Zhuang, 福本一朗, Gary Reynolds, Sylvie Durant, James Beesley, John Herbert, Helen Sheldon, 川崎卓也, Sharon Sanderson, Katie Glen, А.И. Даньшин, Helen M. McGettrick, Philipp Antczak, Francesco Falciani, Gerard B. Nash, Zsuzsanna Nagy, Roy Bicknell	2011	86
16	Development of a new bimodal imaging methodology: a combination of fluorescence microscopy and high‐resolution secondary ion mass spectrometry Journal of Microscopy ·Laith A. Abdul Razak, Martin Christlieb, Markus Schröder, Helen Sheldon, Adrian L. Harris, C.R.M. Grovenor	2010	23
17	Copper chelator ATN-224 inhibits endothelial function by multiple mechanisms Microvascular Research ·Sarah Lowndes, Helen Sheldon, Shijie Cai, Jennifer M. Taylor, Adrian L. Harris	2009	34
18	Phase I/II Trial of Bevacizumab and Radiotherapy for Locally Advanced Inoperable Colorectal Cancer: Vasculature-Independent Radiosensitizing Effect of Bevacizumab Clinical Cancer Research ·Michael I. Koukourakis, Alexandra Giatromanolaki, Helen Sheldon, Francesca M. Buffa, George Kouklakis, Jiannis Ragoussis, Efthimios Sivridis, Adrian L. Harris	2009	46
19	hsa-miR-210 Is Induced by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer Clinical Cancer Research ·Carme Camps, Francesca M. Buffa, Stefano Colella, John Moore, Christos Sotiriou, Helen Sheldon, Adrian L. Harris, Jonathan Gleadle, Jiannis Ragoussis Hit paper breakdown →	2008	540
20	Intracellular expression of the truncated extracellular domain of c-erbB-3/HER3 Cellular Signalling ·Radhika Srinivasan, Chi Moon, Helen Sheldon, Helen C. Hurst, Catherine Sarraf, William J. Gullick	2001	17

About Helen Sheldon

Helen Sheldon is a scholar working on Cancer Research, Immunology and Allergy, Molecular Biology, Rheumatology and Cell Biology, having authored 32 papers that have together received 2.4k indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (8 papers), Cancer, Hypoxia, and Metabolism (7 papers), MicroRNA in disease regulation (5 papers), Cancer-related molecular mechanisms research (4 papers), Cell Adhesion Molecules Research (4 papers), Extracellular vesicles in disease (3 papers), Axon Guidance and Neuronal Signaling (2 papers) and HER2/EGFR in Cancer Research (2 papers). The work is most often cited by research in Cancer Research (1.4k citations), Molecular Biology (1.9k citations), Immunology and Allergy (85 citations), Oncology (329 citations) and Immunology (241 citations). Helen Sheldon has collaborated with scholars based in United Kingdom, United States and Greece. Frequent co-authors include Adrian L. Harris, Francesca M. Buffa, Jiannis Ragoussis, Christos Sotiriou, Jonathan Gleadle, Stefano Colella, John Moore, Carme Camps, Russell Leek and Richard C.A. Sainson. Their work appears in journals such as Oncotarget, Cancer Research, Clinical Cancer Research, Angiogenesis and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact